Designed for women diagnosed with breast cancer
WEDNESDAY, Dec. 9, 2015 (HealthDay News) — The Dignitana DigniCap Cooling System cap has been approved by the U.S. Food and Drug Administration to help prevent hair loss in women undergoing chemotherapy for breast cancer.
A computer-controlled system circulates cooled liquid to the cap during chemotherapy. This is designed to constrict blood vessels in the scalp, limiting the amount of chemotherapy drugs that reach the hair follicles, the agency said in a news release.
In clinical testing, more than two-thirds of women who wore the cap reported losing less than half of their hair. And the likelihood of chemotherapy drugs missing an isolated cluster of breast cancer cells in the scalp because of the cap was “extremely rare,” the FDA said. The most common side effects of the cap included headache, neck and shoulder pain, chills, and pain associated with wearing the cap for extended periods.
But since the cap doesn’t work with all chemotherapy drugs, any woman interested in using the product should speak with her doctor, the FDA advised.
The product is produced by Dignitana Inc., based in Lund, Sweden.
Gap Found Between Awareness of Breast Cancer Risk and Risk-Reducing Behavior 
Exercise Intervention Linked to Improved Attention, Memory in Breast Cancer 
Dense Breast Notification Linked to Increase in Use of Supplemental Ultrasound 
Mammography Trials Yield Excess-Incidence Patterns Consistent With Low Overdiagnosis 
Lower Breast, Cervical Cancer Screening Seen for Adults With Disabilities 
Alcohol-Attributable Cancer Mortality Has Increased Significantly in the U.S. 
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer 
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer .jpg)
